秋水仙碱治疗54例严重慢性肾脏病患者晶体性关节炎发作的安全性与疗效
该研究前瞻性收集了2020年9月至2021年9月住院的54例严重慢性肾脏病(估算肾小球滤过率<30 mL/min)患者共62次秋水仙碱处方,用于治疗痛风或焦磷酸钙沉积病发作。初始剂量≤0.5 mg/日者占47/62(75.8%),无剂量超过1 mg/日,中位疗程6天。47/61(77%)例耐受良好,未报告严重不良事件;医疗团队认为48/58(83%)例完全有效。
要点
- 严重慢性肾脏病患者使用减量秋水仙碱治疗晶体性关节炎发作,47/61(77%)例耐受良好。
- 初始剂量≤0.5 mg/日者占47/62(75.8%),无剂量超过1 mg/日,中位疗程6天。
- 未报告严重不良事件,医疗团队认为48/58(83%)例完全有效。
核心结论
- 在54例严重慢性肾脏病患者中,使用减量秋水仙碱治疗晶体性关节炎发作大多有效且耐受良好,未出现任何严重不良事件。
研究设计与样本
- 前瞻性收集2020年9月至2021年9月住院的严重慢性肾脏病(估算肾小球滤过率<30 mL/min)患者所有用于晶体性关节炎发作的秋水仙碱处方,从第1天至第11天收集临床与生物学安全性及有效性数据。
- 共纳入54例患者(中位年龄75岁,IQR 67-83),对应62次秋水仙碱处方(病例);12例(22%)患者接受透析。
主要发现
- 处方对应58例痛风发作、1例焦磷酸钙沉积病及3例两者兼有。
- 初始秋水仙碱剂量≤0.5 mg/日者47/62例(75.8%),无剂量超过1 mg/日(中位疗程6天,IQR 3-11)。
- 47/61例(77%)耐受良好,未报告严重不良事件。
- 医疗团队认为48/58例(83%)完全有效。
- 住院主要原因包括心力衰竭(31.5%)、急性肾衰竭(22.2%)、感染(18.5%)或急性关节发作(9.3%);59.3%患者有糖尿病。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Colchicine, commonly used in gout flare, is contraindicated in severe chronic kidney disease (CKD) (estimated glomerular filtration rate <30 mL/min). However, in this context, there are few alternatives, and colchicine use persists. We evaluated the tolerance of colchicine and its efficacy in patients with severe CKD. PATIENTS AND METHODS: All prescriptions of colchicine for managing crystal-induced arthritis flare (gout or calcium pyrophosphate deposition (CPPD) disease) in a hospitalised patient with severe CKD were screened from September 2020 to September 2021. After patient consent and treatment information, clinical and biological safety and efficacy data were prospectively collected from day 1 (D1) to D11. RESULTS: We included 54 patients (median age 75 years (IQR 67-83)) with 62 colchicine prescriptions (cases). Twelve (22%) patients were on dialysis. The main reason for hospitalisation was heart failure (31.5%), acute renal failure (22.2%), infection (18.5%) or an acute joint episode (9.3%). In total, 59.3% of patients had diabetes. The prescriptions concerned 58 cases of gout flares, 1 case of CPPD and 3 cases of both. Initial colchicine dosages were ≤0.5 mg/day in 47/62 (75.8%) cases; no dosage exceeded 1 mg/day (median duration of 6 days (IQR 3-11)). Colchicine was well tolerated in 47/61 (77%) cases. No serious adverse event was reported. Colchicine was considered completely effective by the medical team in 48/58 (83%) of cases. CONCLUSION: The use of colchicine, at reduced doses, was mostly effective to treat crystal-induced arthritis flare in 54 patients with severe CKD and was well tolerated, without any serious adverse events.
引用
- Bausson J, Keller N, Von Hunolstein JJ, et al. Safety and efficacy of colchicine in crystal-induced arthritis flare in 54 patients with severe chronic kidney disease. RMD Open. 2024. PMID: 38296804. doi:10.1136/rmdopen-2023-003872
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。